Well keeping the glass half full viewpoint there's quite a few possibilities:
- Nameplate production achieved over the last week (or longer period) - although that could have been an announcement not a trading halt;
- The HP scoping study is the operational update and the numbers in it warrant a trading halt while is its signed off by the board;
- HP test work has resulted in a lower capex solution meaning HP is operationally more advanced than expected;
- Forecast production costs/dmtu are below the $2.91/t - but given the last quarterly this is unlikely;
- They have been given a heads-up that smelter credits will be confirmed on Friday and paid earlier than forecast;
- There is sufficient clarity on the equipment needed for higher production volumes that expansion is now being confirmed;
- They are really close to signing an off-take customer for HP and expect to sign over Friday/the weekend;
- Full-year forecasts have been prepared for revenue and expenses for the remainder of the financial year. They imply a share price stronger than implied by the current share price and the trading halt is the time delay between confirming the forecast and getting board approval for the information to be released;
- Process changes around beneficiation have increased the ore grade beyond 33% (or 33.7%);
- Presentation pack material for the AGM is clarifying operational uncertainties that have been voiced by several on various E25 channels. The clarification and representation around these uncertainties is price sensitive as it unpacks the noise to a clear picture/forecast (so elements like pre-payments/accruals and start-up costs vs ongoing and start-up inefficiencies that are disappearing provide a clear forecast cost/dmtu).
- Forums
- ASX - By Stock
- Ann: Trading Halt
E25
element 25 limited
Add to My Watchlist
0.00%
!
22.5¢

Well keeping the glass half full viewpoint there's quite a few...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $51.43M |
Open | High | Low | Value | Volume |
22.5¢ | 22.5¢ | 21.5¢ | $21.94K | 100.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2779 | 21.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.5¢ | 62609 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2779 | 0.215 |
3 | 28857 | 0.210 |
2 | 8107 | 0.205 |
7 | 59405 | 0.200 |
3 | 13077 | 0.195 |
Price($) | Vol. | No. |
---|---|---|
0.225 | 62609 | 2 |
0.230 | 72958 | 1 |
0.235 | 24800 | 2 |
0.240 | 252084 | 2 |
0.245 | 21276 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
E25 (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online